The Real Story cover image

How close are we to ending Alzheimer's?

The Real Story

CHAPTER

The Cost of Alzheimer's Treatments

The DINANIMAB significantly slowed cognitive and functional decline in early symptomatic Alzheimer's disease. The drugs rely on early diagnosis and the cost per patient is high, will governments want to pay? And what risk do patients run if they choose to try these medicines? "You get some brain swelling immediately after often the first or second dose"

00:00
Transcript
Play full episode

Remember Everything You Learn from Podcasts

Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
App store bannerPlay store banner